Daiichi Sankyo and Charleston Laboratories announce collaboration
7 August 2014 | By Daiichi Sankyo
...to develop and commercialize novel, fixed-dose combination hydrocodone products for pain and opioid-induced nausea and vomiting in the US.
List view / Grid view
News
Yabao Pharmaceuticals and Changzhou Le Sun Pharmaceuticals Ltd. enter an innovative partnership to develop early-stage oncology compound
6 August 2014 | By Yabao Pharmaceutical Co, Inc
Yabao Pharmaceutical Co, Inc. announced a strategic partnership with Changzhou Le Sun Pharmaceuticals Ltd.to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is under pre-clinical development...
Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
Allied Minds and Bristol-Myers Squibb form new enterprise to advance discoveries of biopharmaceutical innovations at leading U.S. academic research
4 August 2014 | By Bristol-Myers Squibb Company
Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S...
Roche’s RoACTEMRA receives CHMP positive opinion in Europe for use in patients with early rheumatoid arthritis (RA) not previously treated with methotrexate (MTX)
4 August 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab, also known as ACTEMRA) has received a positive opinion from the Committee for Medicinal Products for Human Use for use in Europe...
Zealand and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicines
4 August 2014 | By Boehringer Ingelheim & Zealand Pharma
Zealand Pharma and Boehringer Ingelheim jointly announced a new global exclusive licence, research and development collaboration...
AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
European CHMP adopts positive opinion for Gilead’s zydelig® (idelalisib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma
25 July 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig®...
Gilead announces new agreement with Medicines Patent Pool for access to medicines in developing world countries
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
Teva completes acquisition of Labrys
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
Amgen announces positive Phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis
18 July 2014 | By Amgen
Analysis shows study met primary and all secondary endpoints AMG 416 is a novel calcimimetic administered intravenously...
Roche announces phase II clinical results of crenezumab in Alzheimer’s disease
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
Pfizer to Acquire InnoPharma, Inc.
17 July 2014 | By Pfizer
Pfizer Inc. and InnoPharma, Inc. announced that they have entered into an agreement under which Pfizer will acquire InnoPharma...
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
